Dermapharm Holding SE : Q1 2022 due 18 May – nice growth rate on a low base
>BioNTech collaboration helping Q1 - For Q1 2022 we forecast revenues of € 242m, and adj. EBITDA of € 78.9m and EPS of € 0.83. This in particular implies 14% y-o-y sales growth and 24% y-o-y adj. EBITDA growth. The main driver will have been branded pharmaceuticals again with revenues estimated to have been up by c. 20% y-o-y (+5% underlying excl. BioNTech) and adj. EBITDA +25% y-o-y. The key driver is set to be the BioNTech collaboration again (€ 35m revenues vs € 15...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.